SG Americas Securities LLC Has $392,000 Position in Zymeworks Inc. (NYSE:ZYME)

SG Americas Securities LLC increased its holdings in shares of Zymeworks Inc. (NYSE:ZYME) by 30.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,782 shares of the company’s stock after buying an additional 6,239 shares during the period. SG Americas Securities LLC’s holdings in Zymeworks were worth $392,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its position in Zymeworks by 0.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 132,798 shares of the company’s stock worth $1,667,000 after buying an additional 650 shares during the period. FMR LLC raised its stake in Zymeworks by 84.2% in the third quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after purchasing an additional 1,525 shares in the last quarter. Stifel Financial Corp grew its position in Zymeworks by 2.1% during the third quarter. Stifel Financial Corp now owns 73,654 shares of the company’s stock valued at $924,000 after acquiring an additional 1,540 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Zymeworks by 13.2% in the second quarter. The Manufacturers Life Insurance Company now owns 22,695 shares of the company’s stock worth $193,000 after purchasing an additional 2,653 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new position in Zymeworks during the third quarter valued at $47,000. Institutional investors own 92.89% of the company’s stock.

Insider Activity

In related news, insider Paul Andrew Moore sold 21,200 shares of Zymeworks stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $316,304.00. Following the sale, the insider now directly owns 14,741 shares of the company’s stock, valued at approximately $219,935.72. The trade was a 58.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ecor1 Capital, Llc bought 16,692 shares of Zymeworks stock in a transaction on Thursday, December 26th. The shares were acquired at an average cost of $14.38 per share, for a total transaction of $240,030.96. Following the completion of the acquisition, the director now directly owns 14,720,931 shares in the company, valued at approximately $211,686,987.78. The trade was a 0.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 603,539 shares of company stock valued at $8,384,708 and have sold 89,601 shares valued at $1,336,847. 1.92% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ZYME has been the subject of a number of recent research reports. Wells Fargo & Company boosted their price target on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective for the company in a research note on Monday, December 16th. Leerink Partnrs raised Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Citigroup boosted their price objective on Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a report on Monday, November 4th. Finally, Stifel Nicolaus upped their price objective on Zymeworks from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.17.

Zymeworks Trading Up 0.7 %

Shares of NYSE:ZYME opened at $14.70 on Tuesday. The stock has a market capitalization of $1.01 billion, a PE ratio of -9.80 and a beta of 1.10. Zymeworks Inc. has a 1 year low of $7.97 and a 1 year high of $17.70. The firm has a fifty day moving average price of $14.10 and a 200 day moving average price of $13.06.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.